Walleye Capital’s Arcturus Therapeutics ARCT Stock Holding History

Walleye Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$6	–	4355
2025 Q4	$6	Buy	+1	New	+$11	﹤0.01%	4484
2025 Q1	–	Sell	-10,393	Closed	-$176K	–	4225
2024 Q4	$176K	Buy	+10,393	New	+$196K	﹤0.01%	3848
2024 Q3	–	Sell	-6,695	Closed	-$163K	–	5244
2024 Q2	$163K	Buy	+6,695	New	+$203K	﹤0.01%	4441
2022 Q3	–	Sell	-67,978	Closed	-$1.07M	–	3206
2022 Q2	$1.07M	Buy	+67,978	New	+$1.33M	0.03%	617
2021 Q2	–	Sell	-8,567	Closed	-$354	–	1334
2021 Q1	$354	Buy	+8,567	New	+$511K	0.02%	707

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's ARCT Position: Q1 2026 in Review

Walleye Capital sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 1 share — an estimated $6 sold.

Walleye Capital first reported a position in ARCT in Q1 2021 and held it in 5 quarters. The position peaked at $1.07M in Q2 2022. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

Walleye Capital reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 1 Arcturus Therapeutics share in Q1 2026, an estimated $6.
Walleye Capital first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 5 quarters.
Walleye Capital's Arcturus Therapeutics position peaked at $1.07M in Q2 2022.
124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.